[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100549326":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":39,"centralContacts":44,"locations":50,"responsibleParty":63,"collaborators":10,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":67,"sex":73,"minAge":74,"maxAge":10,"enrollmentInfo":75,"targetDuration":10,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":89,"whyStopped":10,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"University Hospital, Toulouse","OTHER",[8,14,18,21],{"label":9,"type":6,"description":10,"interventionNames":11},"patients with isolated cutaneous mastocytosis with associated skin involvement - RNAseq",null,[12,13],"Genetic: scRNAseq","Procedure: two Skin biopsies",{"label":15,"type":6,"description":10,"interventionNames":16},"patients with mastocytosis indolent systemic with associated skin involvement",[17],"Procedure: one Skin biopsies",{"label":19,"type":6,"description":10,"interventionNames":20},"patients with isolated cutaneous mastocytosis with associated skin involvement",[17],{"label":22,"type":6,"description":10,"interventionNames":23},"patients with mastocytosis indolent systemic with associated skin involvement - RNAseq",[12,13],[25,30,35],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":10},"GENETIC","scRNAseq","A blood test tube (only for scRNAseq, 2 tubes of 10 ml per patient)",[9,22],{"type":31,"name":32,"description":33,"armGroupLabels":34,"otherNames":10},"PROCEDURE","two Skin biopsies","2 skin biopsies from a lesional area",[9,22],{"type":31,"name":36,"description":37,"armGroupLabels":38,"otherNames":10},"one Skin biopsies","1 skin biopsies from a lesional area",[19,15],[40],{"name":41,"affiliation":42,"role":43},"Cristina Bulai Livideanu, MD","Toulouse univiversity hospital","PRINCIPAL_INVESTIGATOR",[45],{"name":41,"role":46,"phone":47,"phoneExt":48,"email":49},"CONTACT","0567778138","+33","livideanu.c@chu-toulouse.fr",[51],{"facility":52,"status":10,"city":53,"state":10,"zip":54,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":10},"University Hospital","Toulouse","31059","France","FR",{"type":58,"coordinates":59},"Point",[60,61],1.44367,43.60426,{"lat":61,"lon":60},{"type":64,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100549326","study-of-cellular-heterogeneity-in-patients-with-mastocytosis-100549326",false,"NCT06432556","Study of Cellular Heterogeneity in Patients With Mastocytosis","Study of Cellular Heterogeneity in Patients With Mastocytosis (MastCellHet) Mastocytosis Cell Heterogeneity","MastCellHet","Inclusion Criteria:\n\n* Criteria related to the study population:\n* Subject affiliated with a social security or insurance scheme\n* Subject who has given written consent to his participation in the study\n* Criteria related to the studied pathology:\n* Subject diagnosed with isolated cutaneous or indolent systemic mastocytosis with associated skin involvement defined according to World Health Organization criteria (and\u002For international criteria for cutaneous mastocytosis)\n* Subjects whose KIT mutation status is known in the skin, bone marrow, and blood\n\nExclusion Criteria:\n\n* Criteria related to the study population:\n* Sun exposure of the biopsied areas expected within the 4 weeks preceding\n* Subjects who have had exposure to sunlight or artificial UV radiation within the 2 weeks preceding inclusion at the biopsied areas\n* Adult patients under legal protection, guardianship, or curatorship\n* Pregnant or lactating women\n* Criteria related to the studied pathology:\n* Subjects with an advanced version of the pathology or advanced systemic mastocytosis (SAMA)\n* Subjects with a known history of allergy or intolerance to local anesthetics\n* Subjects who have previously shown abnormalities in skin healing or any other contraindication to skin biopsy\n* Subjects with recognized addiction to alcoholism or drug abuse\n* Subjects with a hereditary or acquired disorder of hemostasis\n* Subjects with a severe or acute chronic condition judged by the investigator as incompatible with the trial\n* Subjects presenting a clinically incompatible immune deficiency with the study\n* Patients without a well-established diagnosis of mastocytosis\n* Patients included in a therapeutic study for indolent systemic mastocytosis\n* Treatment-related criteria:\n* Any topical or systemic treatment for atopic dermatitis (including phototherapy) ongoing or stopped at least 14 days before the inclusion visit\n* Systemic corticosteroids within the 4 weeks preceding the inclusion visit\n* Ongoing systemic treatment likely to interfere with the healing process\n* Subjects who have undergone physical treatment (radiotherapy, etc.) on the biopsy area in the past 6 months\n* History of treatment or concomitant treatment that may interfere with the conduct of the study as determined by the investigator","ALL","18 Years",{"count":76,"type":77},26,"ESTIMATED","INTERVENTIONAL",[80],"NA","This study will aim to study the heterogeneity of skin-resident mast cells and of blood circulating hematopoietic progenitors in patients suffering from isolated Cutaneous Mastocytosis and from systemic Mastocytosis with skin lesions.",[83],"Mastocytosis",[83,85,86,87,88],"Mast cells","Cellular heterogeneity","CD 45+","CD 34+","NOT_YET_RECRUITING","2024-05-21",{"date":92,"type":93},"2024-05-29","ACTUAL",{"date":95,"type":77},"2024-06-01",{"date":97,"type":77},"2026-06-15",{"name":5,"class":6},1]